Canopy Growth Corp WEED
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
-
Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum
-
Canopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special Meeting
-
Canopy Growth Expands European Medical Cannabis Supply Into the UK
-
Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline
-
Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations
-
Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now
-
Canopy Growth Secures Renewed EU GMP Certification at Kincardine as European Medical Cannabis Business Grows
Trading Information
- Previous Close Price
- CA$1.27
- Day Range
- CA$1.23–1.28
- 52-Week Range
- CA$1.18–3.28
- Bid/Ask
- CA$1.25 / CA$1.27
- Shares Outstanding
- 423.04M
- Market Cap
- CA$528.80M
- Volume/Avg
- 499,828 / 737,425
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,128
- Website
- https://www.canopygrowth.com
Valuation
|
Metric
|
WEED
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.77 |
Price/Sales | 1.52 |
Price/Cash Flow | — |
Price/Earnings
WEED
Financial Strength
|
Metric
|
WEED
|
|---|---|
Quick Ratio | 2.27 |
Current Ratio | 3.04 |
Interest Coverage | −5.04 |
Quick Ratio
WEED
Profitability
|
Metric
|
WEED
|
|---|---|
Return on Assets (Normalized) | −8.19% |
Return on Equity (Normalized) | −12.88% |
Return on Invested Capital (Normalized) | −6.07% |
Return on Assets
WEED
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|XZ>P^?Z& | LOCK|n%gG | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|w!>zFnCb | LOCK|&W<yc | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|tQl^Nn | LOCK|PV# | $39B | |||
| Zoetis Inc Class A
ZTS
| LOCK|@M^Ns%m | LOCK|MB | $29B | |||
| Viatris Inc
VTRS
| LOCK|<%$xr< | LOCK|l#q | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Bg | LOCK|@wZ | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|Z^J^xXp | LOCK|QW | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|mtXr?! | LOCK|$G! | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|v@#&y! | LOCK|%@vS> | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|XZ^t%c | LOCK|x@ | $2B |
United States